Braveheart Investment Group plc Update on the Paraytec AD Scanner project

TIDMBRH

Braveheart Investment Group plc

14 June 2021

Reach - a non-regulatory announcement

AIM: BRH

14 June 2021

Braveheart Investment Group plc

("Braveheart" or the "Group")

Update on the P araytec AD Scanner project

Paraytec's grant funded project to deploy its ActiPix(TM) technology in the field of Alzheimer's disease (AD) diagnosis, working with a pan-European consortium of Karolinska Institute, Biomotif, Vrije University Medical Centre Amsterdam (VUMC) and MS Vision is progressing well. Prototype instruments are being built, to test blood for protein biomarkers. If successful, these instruments will be used by clinicians aiming to more accurately diagnose patients and monitor their treatment.

Pooled plasma samples from AD patients and healthy individuals have been tested in the laboratory and produced good results. In the next month, VUMC will begin testing the system with plasma samples from individual AD patients, to assess the pre-clinical performance and correlation with clinical diagnosis.

The first fully assembled instrument, incorporating Paraytec's detector technology, has been produced by MS Vision and shipped to Karolinska Institute in Sweden for testing. The instrument uses capillary isoelectric focusing (cIEF), together with ActiPix technology, to measure the level of protein biomarkers (abnormal proteoforms) in blood samples. If present, these biomarkers are indicative of the likely rate of mental decline for a given AD patient. This is important because such information could be used by clinicians in early diagnosis to differentiate AD patients from those with mild cognitive impairment, and also by researchers to help develop better drugs to counter this devastating disease.

Research conducted by the Alzheimer's Society shows that, in 2019, there were over 850,000 people with dementia in the UK. The Society considers that more than 520,000 people in the UK have dementia caused by Alzheimer's disease and this figure is set to rise.

https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease#content-start

The project is due to end in August 2021 and discussions regarding commercialisation are ongoing with system manufacturers who are already part of the project team.

During the project Paraytec has developed new cIEF analytical techniques which dramatically improve signal to noise ratios, far beyond those of competitor instrumentation. The Paraytec team believes this breakthrough will lead to new applications for its ActiPix technology, for example in the biopharmaceutical industry for quality control in manufacturing therapeutic antibodies.

 
   For further 
    information: 
 
                      Braveheart Investment Group plc              Tel: [phone] 
                      Viv Hallam, Executive Director 
 
                      Allenby Capital Limited (Nominated Adviser   Tel: [phone] 
                       and Joint Broker) 
                      David Worlidge / George Payne 
 
                      Peterhouse Capital Limited (Joint Broker)    Tel: [phone] 
                      Heena Karani / Lucy Williams 
 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUSOWRANUNARR

(END) Dow Jones Newswires

June 14, 2021 04:40 ET (08:40 GMT)